RU2019139387A - Способы селективного лечения астмы с использованием антагонистов il-17 - Google Patents

Способы селективного лечения астмы с использованием антагонистов il-17 Download PDF

Info

Publication number
RU2019139387A
RU2019139387A RU2019139387A RU2019139387A RU2019139387A RU 2019139387 A RU2019139387 A RU 2019139387A RU 2019139387 A RU2019139387 A RU 2019139387A RU 2019139387 A RU2019139387 A RU 2019139387A RU 2019139387 A RU2019139387 A RU 2019139387A
Authority
RU
Russia
Prior art keywords
seq
patient
antagonist
treatment
less
Prior art date
Application number
RU2019139387A
Other languages
English (en)
Russian (ru)
Inventor
Сара Шмидт ГРЭНТ
Шамса КАЗАНИ
Эдвард ХОХЛОВИЧ
Джейсон ЛАРАМИ
Роберт Мартин СТРИТЕР
Триша Энн ТОРНТОН-УЭЛЛЗ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2019139387A publication Critical patent/RU2019139387A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6854—Immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/12—Pulmonary diseases
    • G01N2800/122—Chronic or obstructive airway disorders, e.g. asthma COPD
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
RU2019139387A 2017-05-05 2018-05-04 Способы селективного лечения астмы с использованием антагонистов il-17 RU2019139387A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762501806P 2017-05-05 2017-05-05
US62/501,806 2017-05-05
PCT/IB2018/053106 WO2018203289A1 (en) 2017-05-05 2018-05-04 Methods of selectively treating asthma using il-17 antagonists

Publications (1)

Publication Number Publication Date
RU2019139387A true RU2019139387A (ru) 2021-06-07

Family

ID=62245372

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019139387A RU2019139387A (ru) 2017-05-05 2018-05-04 Способы селективного лечения астмы с использованием антагонистов il-17

Country Status (13)

Country Link
US (1) US10676522B2 (https=)
EP (1) EP3619536A1 (https=)
JP (1) JP2020518604A (https=)
KR (1) KR20190142398A (https=)
CN (1) CN110582702A (https=)
AU (1) AU2018263159A1 (https=)
BR (1) BR112019023141A2 (https=)
CA (1) CA3062179A1 (https=)
CL (1) CL2019003161A1 (https=)
MX (1) MX2019013160A (https=)
RU (1) RU2019139387A (https=)
TW (1) TW201842933A (https=)
WO (1) WO2018203289A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3689907A1 (en) * 2019-01-31 2020-08-05 Numab Therapeutics AG Antibodies targeting il-17a and methods of use thereof
CA3174345A1 (en) * 2020-04-17 2021-10-21 Eli Lilly And Company Treatment of acute respiratory distress syndrome with anti-il17 antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0308324D0 (en) 2003-04-10 2003-05-14 Piezoptic Ltd A chemical sensing device
CN1898564A (zh) * 2003-12-24 2007-01-17 惠氏公司 治疗哮喘的方法
GB0417487D0 (en) 2004-08-05 2004-09-08 Novartis Ag Organic compound
GB0425569D0 (en) 2004-11-19 2004-12-22 Celltech R&D Ltd Biological products
CN101326195B9 (zh) 2005-12-13 2022-11-11 伊莱利利公司 抗il-17抗体
GB0612928D0 (en) 2006-06-29 2006-08-09 Ucb Sa Biological products
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
EP2631302A3 (en) 2008-03-31 2014-01-08 Genentech, Inc. Compositions and methods for treating and diagnosing asthma
JP5581323B2 (ja) 2008-09-29 2014-08-27 ロシュ グリクアート アクチェンゲゼルシャフト ヒトｉｌ１７に対する抗体およびその使用
LT2953969T (lt) * 2013-02-08 2019-12-10 Novartis Ag Anti-il-17a antikūnai ir jų panaudojimas autoimuninių ir uždegiminių ligų gydymui
SG11201603127WA (en) * 2013-10-23 2016-05-30 Genentech Inc Methods of diagnosing and treating eosinophilic disorders
US20160000936A1 (en) * 2014-06-10 2016-01-07 Abbvie Inc. Biomarkers for inflammatory disease and methods of using same
MX2017003216A (es) * 2014-09-10 2017-05-23 Novartis Ag Uso de antagonistas de il-17 para inhibir la progresion del daño estructural en pacientes con artritis psoriasica.
GB201508832D0 (en) 2015-05-22 2015-07-01 Novartis Ag A method for detecting an analyte

Also Published As

Publication number Publication date
MX2019013160A (es) 2020-02-05
EP3619536A1 (en) 2020-03-11
CN110582702A (zh) 2019-12-17
JP2020518604A (ja) 2020-06-25
KR20190142398A (ko) 2019-12-26
BR112019023141A2 (pt) 2020-07-28
US20180319881A1 (en) 2018-11-08
US10676522B2 (en) 2020-06-09
WO2018203289A1 (en) 2018-11-08
TW201842933A (zh) 2018-12-16
CA3062179A1 (en) 2018-11-08
AU2018263159A1 (en) 2019-11-07
CL2019003161A1 (es) 2020-02-07

Similar Documents

Publication Publication Date Title
Eghbali-Fatourechi et al. Role of RANK ligand in mediating increased bone resorption in early postmenopausal women
US7138230B2 (en) Systems and methods for characterizing kidney diseases
EP2564202B1 (en) Methods for detecting anti-drug antibodies
CN102576015B (zh) 预测银屑病关节炎患者对抗TNFα抗体的临床反应的血清标记物
Thoren Mass spectrometry methods for detecting monoclonal immunoglobulins in multiple myeloma minimal residual disease
RU95108591A (ru) Способ определения состояния сепсисного заболевания
AR063125A1 (es) Ensayo elisa para la deteccion de vegf
JP6812521B2 (ja) クロモグラニンａを検出するための免疫アッセイ法および抗体
Chan et al. Rapid analysis of fatty acid-binding proteins with immunosensors and immunotests for early monitoring of tissue injury
CN118063608A (zh) 针对三碘甲状腺原氨酸的单克隆抗体、基于其的检测试剂及其应用
Scolnik et al. CD34 and CD117 are overexpressed in AML and may be valuable to detect minimal residual disease
RU2019139387A (ru) Способы селективного лечения астмы с использованием антагонистов il-17
Krischer et al. Comparative Analysis of the Sensitivity, Specificity, Concordance, and 5-Year Predictive Power of Diabetes-Related Autoantibody Assays
US20020004212A1 (en) Detection of surface-associated human leukocyte elastase
JP2020518604A5 (https=)
CN116482345B (zh) 用于检测双靶点药物受体占有率的方法
CN109997043B (zh) 护理点测定法
CN118994407A (zh) 抗噻奈普汀的抗体或其抗原结合片段及其应用
AU2024262099A1 (en) Diagnosis of late-stage hepatocellular carcinoma
US20190064177A1 (en) Incorporating competitive binding information into molecular array analysis to generate function networks of interactions
EP4286850A1 (en) Immunological assay method
RU2803276C1 (ru) Способ прогнозирования когнитивных нарушений у пациентов с сотрясением головного мозга и ушибом головного мозга лёгкой степени тяжести
CA2870320C (en) Rapid test for cellular fibronectin
WO2001086292A2 (en) Ipg assay
KR20250015147A (ko) 자폐증 장애 진단용 조성물 및 키트

Legal Events

Date Code Title Description
FA93 Acknowledgement of application withdrawn (no request for examination)

Effective date: 20210505